Leerink Partners Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Tenax Therapeutics with an Outperform rating and set a price target of $16.
October 24, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Tenax Therapeutics with an Outperform rating and a price target of $16, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a price target of $16 by Leerink Partners suggests a positive outlook for Tenax Therapeutics. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100